ArticleFrontiers in medicine2026
Clinical characteristics and prognosis of immunoglobulin light chain amyloidosis patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the prognostic factors associated with overall survival (OS) in patients diagnosed with immunoglobulin light chain (AL) amyloidosis, with the goal of improving risk stratification and patient management. Methods: A retrospective cohort analysis was conducted on 87 patients diagnosed with AL amyloidosis at the People's Hospital of Ningxia Hui Autonomous Region from January 2016 to December 2023. Demographic, clinical, laboratory data, and survival status were collected. Univariable and multivariable Cox regression analyses were used to identify significant predictors of OS. Kaplan-Meier survival curves and restricted cubic spline (RCS) analysis were employed to evaluate risk stratification. Results: The median overall survival was 22.0 months (95% CI: 15.2-28.8), and the median follow-up duration was 39.0 months (95% CI: 29.2-48.8). Our results revealed that higher bone marrow plasma cell count (BMPCs), myeloma presence, heart failure, and increased fibrinogen degradation products (FDP) were significantly associated with poor survival outcomes. The median survival time for patients with BMPCs >12% was 13 months, compared to 36 months for those with lower BMPCs. Myeloma presence was the strongest predictor of survival, with a median survival of 15 months for those with myeloma versus 36 months for those without. Multivariable analysis identified that myeloma ( Conclusion: Elevated BMPCs, concurrent myeloma, heart failure, and increased FDP levels were associated with poor OS of AL amyloidosis patients. These factors could be incorporated into clinical decision-making to better stratify risk and guide treatment strategies for AL amyloidosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.